April 9, 2021
Hisamitsu Pharmaceutical’s group revenue dwindled 18.8% in the year ended February, suffering a near-20% plunge for ethical drug sales in Japan alone, in the face of price cuts and generic erosions as well as hospital avoidance caused by COVID-19. In...read more